Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2, Randomized, Open-Label, Multicentre, Comparative 3 Arm Study to Evaluate the Efficacy And Safety of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults

NCT07840105 is registered in ClinicalTrials.gov with Wockhardt as lead sponsor.

NCT NCT07840105
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07840105 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2, Randomized, Open-Label, Multicentre, Comparative 3 Arm Study to Evaluate the Efficacy And Safety of Intravenous Ertapenem-zidebactam Versus Ceftazidime-Avibactam in the Treatment of Complicated Urinary Tract Infection or Acute Pyelonephritis in Adults
Lead sponsor
Wockhardt
Phase
Phase 2
Overall status
Not yet recruiting
Start date
September 30, 2026
Completion date
September 1, 2027
Enrollment
279 (estimated)
Sites
19

Conditions

As the registry lists them; a condition with its own page is linked.

acute pyelonephritis, complicated urinary tract infections(cuti)